Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
02.06. | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | 649 | Xetra Newsboard | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
26.05. | Delisting of Lipidor AB from Nasdaq First North Growth Market | 264 | GlobeNewswire | On May 26, 2025, Lipidor AB was declared bankrupt by the Stockholm District Court.
According to item 8.2.7 of the Nasdaq First North Growth Market Rulebook, the exchange may decide to delist... ► Artikel lesen | |
26.05. | XFRA L7R: AUSSETZUNG/SUSPENSION | 139 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILLIPIDOR AB L7R SE0012558617... ► Artikel lesen | |
26.05. | Suspension of Trading in Lipidor AB at FNSE | 202 | GlobeNewswire | 2025-05-26T06:33:44Z
Suspension
At Trading Venue FNSE
Due to Non Disclosure Of
Inside Information About The Issuer Or Financial Instrument
Ongoing:
True
Comments: Nasdaq Stockholm has, to the extent... ► Artikel lesen | |
25.05. | Lipidor AB: Lipidor applies for bankruptcy | 257 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 25th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the Company's board has resolved to file for bankruptcy on behalf of the Company. The... ► Artikel lesen | |
24.05. | Lipidor AB: Lipidor announces today negative results from the company's Phase III clinical study of AKP02G2 for psoriasis | 139 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 24th May 2025 - (Nasdaq First North: LIPI) reports negative results from a Phase III clinical study of the AKP02G2 cutaneous spray for mild to moderate plaque psoriasis. The study... ► Artikel lesen | |
19.05. | Lipidor AB: Lipidor announces database lock in its Phase III clinical study of the psoriasis candidate AKP02G2 | 155 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 19th May 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) announces today that the company's Phase III study of AKP02G2 for the treatment of psoriasis has reached... ► Artikel lesen | |
17.03. | Lipidor AB: Lipidor announces all patients enrolled in ongoing Phase III study | 170 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 17th March 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that all patients in the ongoing Phase III study for the drug candidate AKP02G2 have been... ► Artikel lesen | |
LIPIDOR Aktie jetzt für 0€ handeln | |||||
28.02. | Lipidor AB: Lipidor AB (publ) publishes year-end report for 2024 | 244 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 28th February 2025 - Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its year-end report for the period January - December 2024. The report is available... ► Artikel lesen | |
21.01. | Lipidor AB: Lipidor announces half of patients enrolled in ongoing Phase III study | 570 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 21st January 2025 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today announces that half of the patients in the ongoing Phase III study for the drug candidate AKP02G2... ► Artikel lesen | |
20.11.24 | Lipidor AB: Lipidor publishes CEO statement for the quarter: "Study results expected by the end of Q1 2025" | 173 | GlobeNewswire (Europe) | STOCKHOLM, Sweden, 20 November 2024 - Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today provides an update on the business from CEO Ola Holmlund, also announcing a company presentation... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
ORAMED PHARMACEUTICALS | 2,122 | -0,05 % | Scilex Holding Company Announces the Completion of the First Tranche of the Oramed Pharmaceuticals, Inc. Warrant Repurchase | PALO ALTO, Calif., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company ("Scilex" or the "Company") (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing and... ► Artikel lesen | |
OPUS GENETICS | 1,574 | +1,68 % | Opus Genetics, Inc.: Opus Genetics Reports Positive Pediatric Data from OPGx-LCA5 Phase 1/2 Trial in Leber Congenital Amaurosis Type 5 (LCA5) | Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting toxicitiesLasting, durable responses... ► Artikel lesen | |
VERTICAL AEROSPACE | 5,200 | +2,97 % | Vertical Aerospace to Report Q3 Business Update on 4 November 2025 | Vertical Aerospace (Vertical) [NYSE: EVTL], a global aerospace and technology company pioneering electric aviation, today announces that it expects to share a business update pre-market on Tuesday... ► Artikel lesen | |
BOIRON | 26,700 | -2,55 % | Boiron USA: Boiron's Camilia Tummy Receives Top Honors from Baby Innovation Awards | Newtown Square, Pennsylvania--(Newsfile Corp. - June 26, 2025) - Camilia Tummy® has received the "Baby Accessory Product of the Year" in the 2025 Baby Innovation Awards. Now in its fifth year, this... ► Artikel lesen | |
PACIRA BIOSCIENCES | 20,800 | -1,89 % | Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Oct. 03, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in the delivery of innovative, non-opioid pain therapies to transform the lives of... ► Artikel lesen | |
RED LIGHT HOLLAND | 0,023 | -4,49 % | Red Light Holland Corp.: Red Light Holland Receives Official Psilocybin COA Through FDA-Compliant, DEA-Registered Partner, Irvine Labs, USA | Toronto, Ontario--(Newsfile Corp. - September 30, 2025) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland" or the "Company"), an Ontario-based corporation engaged... ► Artikel lesen | |
INNOCARE PHARMA | 2,040 | 0,00 % | InnoCare Pharma: InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore | BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, announced today that HIBRUKA... ► Artikel lesen | |
PHIBRO ANIMAL HEALTH | 34,200 | +1,79 % | Dividendenbekanntmachungen (03.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AEGON LTD BMG0112X1056 - 0,19 EUR AIR LEASE CORPORATION US00912X3026 0,22 USD 0,1889 EUR AMKOR TECHNOLOGY INC US0316521006 0,0826... ► Artikel lesen | |
BAYER | 28,850 | -0,93 % | Panik bei Novo Nordisk, Bayer atmet auf, Hin und Her bei Oracle und Rheinmetall bleibt obenauf | Mit einem neuerlichen Zollhammer schockte US-Präsident Donald Trump in dieser Woche wieder einmal die Märkte. 100 Prozent Aufschläge soll es schon ab Mittwoch auf sämtliche patentierte Arzneimittel... ► Artikel lesen | |
MERCK KGAA | 120,85 | +2,68 % | Merck KGaA: Was feiern die Käufer hier eigentlich genau? | Die Aktie des deutschen Pharmaunternehmens Merck KGaA sah gestern mit +10,05 Prozent den größten Kursgewinn seit Langem. Charttechnisch ist sie damit auf dem Sprung zu einem markanten Kaufsignal. Aber... ► Artikel lesen | |
GSK | 18,775 | -1,21 % | GSK macht Luke Miels zum neuen CEO | DJ GSK macht Luke Miels zum neuen CEO
Von Elena Vardon
DOW JONES--GSK ernennt Luke Miels zum Nachfolger von Emma Walmsley als CEO des britischen Arzneimittelherstellers.
Wie der britische... ► Artikel lesen | |
NOVO NORDISK | 50,65 | +0,02 % | Übernahme im Ozempic-Markt! Jetzt BioNxt Solutions? Novo Nordisk, Elli Lilly und Pfizer kämpfen! | Der Kampf gegen Fettleibigkeit gilt als einer der größten Wachstumsmärkte im globalen Pharmasektor. Schätzungen zufolge könnte der Markt für Adipositas-Therapien bis 2030 ein Volumen von bis zu 150... ► Artikel lesen | |
SCHOTT PHARMA | 21,550 | -1,15 % | EQS-PVR: SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: SCHOTT Pharma AG & Co. KGaA
SCHOTT Pharma AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen | |
ROCKET LAB | 46,200 | -0,43 % | Wochenrückblick 39/2025: Meine stärksten Kurstreiber im Depot waren Almonty, KKR, AeroVironment, Viper Energy, LendingClub. Aber (noch) mehr Action gab' bei Funkwerk, Rocket Lab - und Costco... | Die Top-Werte meines Investmentdepots veröffentliche ich jeweils zum Quartalsende in meinen Investor-Updates und meine Beobachtungsliste aktualisiere ich wöchentlich.Ergänzend gebe ich heute eine kurze... ► Artikel lesen | |
METSERA | 51,90 | +0,39 % | Metsera, Inc.: Metsera Reports Positive Phase 2b Results for First- and Best-in-Class Ultra-long Acting GLP-1 RA Candidate MET-097i, Enabling Rapid Transition into Phase 3 | Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateau Potential for best-in-class tolerability with minimal diarrhea signal, 13% nausea, and 11% vomiting High study and... ► Artikel lesen |